TickerFacts.

Polomar Health Services, Inc. (PMHS): Gross Profit

Annual figures by period end, from SEC filings.

$460.1K
Year ended 2025-12-31
$1.94M
Trailing 12 months to 2026-06-30
+137.1%
3-year compound annual growth
2022-12-31: $34.5K2023-12-31: $37.5K2024-12-31: $30.9K2025-12-31: $460.1K$460.1K
2022-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$460.1Kn/m2026-05-06, From 2025-01-01
2024-12-31$30.9K-17.7%2026-05-06, From 2024-01-01
2023-12-31$37.5K+8.8%2025-05-22, From 2023-01-01
2022-12-31$34.5Kn/a2024-04-15, From 2022-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
Polomar Health Services, Inc. (PMHS)2025-12-31$460.1Kn/m
BioXcel Therapeutics, Inc. (BTAIQ)2025-12-31$478.0K+288.6%
Lexaria Bioscience Corp. (LEXX)2025-08-31$703.2K+53.1%
PMGC Holdings Inc. (ELAB)2025-12-31$185.3Kn/a
Silence Therapeutics plc (SLN)2025-12-31$344.0K-98.9%
Quantum Cyber N.V. (QUCY)2025-12-31$389.8K-32.2%
Onconetix, Inc. (ONCO)2025-12-31$632.9K-40.0%
Scienture Holdings, Inc. (SCNX)2025-12-31$331.5Kn/m
60 Degrees Pharmaceuticals, Inc. (SXTP)2025-12-31$223.8K+0.4%

Compare PMHS, BTAIQ, LEXX, ELAB side by side · Screen every company in Pharmaceutical Preparations ↗